Get started

INC

Discovery inc. Disca double top short positionDiscovery INC looking like it wants to come down, we have a double top on the weekly with bearish divergence on the monthly and the weekly. The top is confirmed on the weekly so we have confirmed divergence on the monthly. as shown i have the neckline which we are currently trading below. I think 31 or 30,5 is a descent target on this. Also i think its imortant to have atleast a daily close below the neckline wich will likely get confirmed today. Goodluck all!! :)
DShort
by IMakeProfit
NUVA BUYBUY signal at 65.73$. Timeframe - 1 week. Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. If you want to see more history of this strategy, I able to show you if you request me. It's one of two signal algo for NUVA. ATTENTION this strategy may has downtrend about 10-15%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NLong
by price_and_time
AT&T INC Levels and Zones to watch! I have finally decided to chart AT&T. Looking for a deeper pull back into the 618 at the 27-29 range. We have momentum slowly turning positive, with some buy signals stacking. Were at the bottom of the bolly band with the failed false breakout of 3 years back into its proper wedge. Lets see what happens. Dividends for all! I want everyone to win! Happy trading, debating and speculating! FOLLOW me for updates, and check out my other charts, which have been 100% accurate.
NYSE:T
by ToddGreen
FDA Approval "coming soon"From a post on ihub- an investor emailed investor relations and received this response $$$ to: info@viadermalicensing.com cc: sales@viadermalicensing.com subject: Update mailed-by: gmail.com Hello, I have a few questions: 1-Can we expect a PR with a FDA approval this week or next for your product for treating Premature Ejaculation? 2-Are sales rolling out this quarter for Viabecline? 3-Will the lawsuit be dropped or settled this quarter? Will ViaDerma prevail? 4-Hasn't the efficacy already been done for Viabecline? Why have you started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds? 5-How much revenue do you expect from the grass roots THC and non-THC Cannabinoids, both in a patch form, roll on and spray signed with the Canadian company? Are your plans to sell licensing agreements to major producers? Thank you ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ info@viadermalicensing.com 3:08 PM (17 hours ago) FDA approval is on track. No delays are expected. Stand by for updates on that Rollout is also still on time and should be out by the of the quarter (one month from now) We received a continuance to submit our reply to the lawsuit. That's usually pretty standard. We will report developments as they happen but we feel very strongly we will prevail. We cant say too much until after we file our official reply with the court Efficacy has been done but the reason for the independent study is to show we do it better. Can't answer any revenue guidance question yet until we release that to the public. Hopefully soon. Stay tuned for more news in the near future. We expect to report on some of these and other developments shortly. Thanks Investor Relations (310) 734 6111
OTC:VDRMLong
by Cryptocol